David Wages

944 total citations
31 papers, 721 citations indexed

About

David Wages is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Wages has authored 31 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Wages's work include Lung Cancer Treatments and Mutations (6 papers), Blood transfusion and management (5 papers) and Epigenetics and DNA Methylation (4 papers). David Wages is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Blood transfusion and management (5 papers) and Epigenetics and DNA Methylation (4 papers). David Wages collaborates with scholars based in United States, Japan and Switzerland. David Wages's co-authors include Irena Melnikova, Laurence Corash, Lily Lin, James L.M. Ferrara, Julie Hambleton, Richard J. Benjamin, Alain C. Mita, Alice Bexon, David A. Smith and Guillaume de La Bourdonnaye and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

In The Last Decade

David Wages

31 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Wages United States 14 235 225 162 152 132 31 721
Iris M. De Cuyper Netherlands 16 132 0.6× 213 0.9× 148 0.9× 54 0.4× 143 1.1× 26 692
Varsha Bhakta Canada 16 130 0.6× 284 1.3× 259 1.6× 87 0.6× 59 0.4× 60 801
Alan Le Canada 10 78 0.3× 341 1.5× 173 1.1× 16 0.1× 284 2.2× 13 939
J. N. Shanberge United States 16 128 0.5× 321 1.4× 87 0.5× 72 0.5× 49 0.4× 42 853
Dianne E. van der Wal Australia 11 68 0.3× 461 2.0× 108 0.7× 24 0.2× 92 0.7× 22 680
Egarit Noulsri Thailand 13 30 0.1× 203 0.9× 216 1.3× 21 0.1× 58 0.4× 50 695
Michael D. Burdick United States 13 118 0.5× 134 0.6× 515 3.2× 13 0.1× 227 1.7× 20 973
J Martinéz United States 16 37 0.2× 294 1.3× 182 1.1× 16 0.1× 55 0.4× 25 997
John A. Cavins United States 13 71 0.3× 235 1.0× 61 0.4× 22 0.1× 81 0.6× 22 482
Hans‐Peter Lohrmann Germany 10 35 0.1× 263 1.2× 99 0.6× 13 0.1× 323 2.4× 18 705

Countries citing papers authored by David Wages

Since Specialization
Citations

This map shows the geographic impact of David Wages's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wages with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wages more than expected).

Fields of papers citing papers by David Wages

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wages. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wages. The network helps show where David Wages may publish in the future.

Co-authorship network of co-authors of David Wages

This figure shows the co-authorship network connecting the top 25 collaborators of David Wages. A scholar is included among the top collaborators of David Wages based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wages. David Wages is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Langer, Corey J., Brendan D. Curti, Charles M. Farber, et al.. (2024). A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2615–2615. 2 indexed citations
2.
Jankú, Filip, Milind Javle, Shiraj Sen, et al.. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129(10). 1537–1546. 1 indexed citations
3.
Matulonis, Ursula A., Justin C. Moser, Siqing Fu, et al.. (2022). A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3101–3101. 3 indexed citations
4.
Borazanci, Erkut, Erika Hamilton, Jacob Thomas, et al.. (2022). A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3097–3097. 3 indexed citations
5.
Reed, Damon R., Sant P. Chawla, Bhuvana A. Setty, et al.. (2021). Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11514–11514. 11 indexed citations
6.
Chawla, Sant P., Jasgit C. Sachdev, David Wages, et al.. (2021). Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).. Journal of Clinical Oncology. 39(15_suppl). 3073–3073. 5 indexed citations
7.
Falchook, Gerald S., Deeksha Vishwamitra, Takayuki Yamada, et al.. (2017). Abstract CT100: First-in-human phase 1 trial of pyrimidine anti-metabolite FF-10502-01 in patients with advanced cancer. Cancer Research. 77(13_Supplement). CT100–CT100. 1 indexed citations
8.
9.
10.
Wu, Yi‐Long, Keunchil Park, Ross A. Soo, et al.. (2011). INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 11(1). 430–430. 66 indexed citations
11.
Mita, Monica, Carolyn D. Britten, Elizabeth Poplin, et al.. (2008). Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). Journal of Clinical Oncology. 26(15_suppl). 3509–3509. 45 indexed citations
12.
Rios, Jorge A., Julie Hambleton, Maurene Viele, et al.. (2006). Viability of red cells prepared with S‐303 pathogen inactivation treatment. Transfusion. 46(10). 1778–1786. 22 indexed citations
13.
Melnikova, Irena & David Wages. (2006). Anti-obesity therapies. Nature Reviews Drug Discovery. 5(5). 369–370. 87 indexed citations
14.
Benjamin, Richard J., Jeffrey McCullough, Paul D. Mintz, et al.. (2005). Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 45(11). 1739–1749. 62 indexed citations
15.
Alarcón, Pedro A. de, Richard J. Benjamin, Marion Dugdale, et al.. (2005). Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 45(8). 1362–1372. 58 indexed citations
16.
Conlan, Maureen G., Adonis Stassinopoulos, George Garratty, et al.. (2004). Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.. Blood. 104(11). 382–382. 13 indexed citations
17.
Hambleton, Julie, David Wages, Melanie Adams, et al.. (2002). Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 42(10). 1302–1307. 54 indexed citations
18.
Wages, David, et al.. (1999). Prevention of Transfusion-Associated Graft-Versus-Host Disease by Photochemical Treatment. Blood. 93(9). 3140–3147. 108 indexed citations
19.
Wages, David, Ilona Staprãns, Julie Hambleton, Nathan M. Bass, & Laurence Corash. (1998). Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma. American Journal of Hematology. 58(4). 285–292. 16 indexed citations
20.
Wages, David, et al.. (1995). Coccidioides immitis presenting as a hyphal form in a ventriculoperitoneal shunt.. PubMed. 119(1). 91–3. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iris M. De Cuyper Breakdown of academic impact, for papers by Varsha Bhakta Breakdown of academic impact, for papers by Alan Le Breakdown of academic impact, for papers by J. N. Shanberge Breakdown of academic impact, for papers by Dianne E. van der Wal Breakdown of academic impact, for papers by Egarit Noulsri Breakdown of academic impact, for papers by Michael D. Burdick Breakdown of academic impact, for papers by J Martinéz Breakdown of academic impact, for papers by John A. Cavins Breakdown of academic impact, for papers by Hans‐Peter Lohrmann
Rankless by CCL
2026